Ocata therapeutics is a clinical stage biopharma company developing regenerative medicine and cell therapy technologies. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration and myopic macular degeneration.
Ocata therapeutics – regenerative ophthalmology
Regenerative medicine is defined as the process of regenerating human cells, tissues or organs to restore or establish normal function. Ocata therapeutics develops innovative new therapies to treat vision loss with the mission of improving the quality of life for millions of patients worldwide. Ocata’s lead clinical program involves Retinal Pigment Epithelium (RPE) Cell Therapy for treating macular degeneration. RPE is a single layer of cells whose presence and integrity in the retina are required for normal vision. Ocata therapeutics is currently conducting clinical trials in the U.S. and U.K. for treating Stargardt’s macular degeneration with the RPE Cell Therapy, and in the U.S. for treating patients with dry age-related macular degeneration. Ocata therapeutics is also developing a Photoreceptor Progenitor Cell Therapy to be used for treating a wide variety of retinal degenerations in diseases where photoreceptors malfunction or die. Furthermore, its Ganglion Progenitor Cell Therapy is a preclinical candidate program. Indeed, in animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells as well as forms new ganglion nerve cells. Moreover, Ocata therapeutics is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness. Thus, Ocata’s preclinical programs involve cell therapies for the treatment of ocular disorders (Stargardt’s Disease, Dry Age-related Macular Degeneration, Myopic Macular Degeneration, Retinis Pigmentosa, Glaucoma, Corneal Blindness, etc…) but also diseases outside the field of ophthalmology (including autoimmune, inflammatory and wound healing-related disorders)
Ocata Therapeutics (NASDAQ Global Market: OCAT), formerly named Advanced Cell Technology, is a biopharma company headquartered in Marlborough (USA). Ocata’s Management Team is composed by Paul Wotton, Robert Lanza, Ted Myles, Eddy Anglade, LeRoux Jooste, John Heffernan and Matthew Vincent. Board of Directors is composed by Michael Heffernan, Robert Langer, Zohar Loshitzer, Gregory Perry, Alan Shapiro and Paul Wotton. Its Scientific Advisory Board spans the continuum of experience from laboratory and translational research to drugs and biologics development through clinical trials. Members of the Scientific Advisory Board are Constance Cepko, George Daley, John Gearhart, Chairman Robert Langer, Michael Longaker and Joseph Vacanti. In 2012, it was calculated that the total economic burden of vision loss and eye disorders in the U.S. alone was nearly $250 Billion, and projected that overall burden to rise to $380 Billion by 2032 and $716 Billion by 2050. The prevalence and costs of vision problems is predicted to grow at an incredible rate of the next few decades due to demographic shifts.
More about Ocata therapeutics : www.ocata.com